Download PDF
Fortschr Neurol Psychiatr 2014; 82(6): 346-360
DOI: 10.1055/s-0034-1366575
Fort- und Weiterbildung
© Georg Thieme Verlag KG Stuttgart · New York

Phasenprophylaxe bipolarer Erkrankungen

Long-term Treatment of Bipolar Disorder
M. Berger
1   Klinik für Psychiatrie und Psychotherapie, Clienia Schlössli, Oetwil am See, Schweiz
,
R. Musil
2   Klinik für Psychiatrie und Psychotherapie der Ludwig-Maximilians-Universität, München
,
F. Seemüller
3   Klinik für Psychiatrie, Psychotherapie und Psychosomatik, kbo-Lech-Mangfall-Klinik Garmisch-Partenkirchen
› Author Affiliations
Further Information

Publication History

Publication Date:
01 August 2014 (online)

    Permissions and Reprints

Corrected by:

Phasenprophylaxe bipolarer ErkrankungenFortschr Neurol Psychiatr 2014; 82(06): E1-E1
DOI: 10.1055/s-0034-1384930

Lernziele

Dieser Artikel soll aktuelle Empfehlungen zur Phasenprophylaxe bipolarer Erkrankungen vermitteln. Zudem werden mögliche Überlegungen bei der Indikationsstellung für eine Langzeittherapie wie auch bei der Auswahl einer passenden pharmakologischen Prophylaxe dargestellt. Darüber hinaus werden Zielsetzungen einer Phasenprophylaxe sowie nicht-pharmakologische Aspekte einer Langzeittherapie erläutert.

 

  • Literatur

  • 1 Goodwin GM, Martinez-Aran A, Glahn DC et al. Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report. Eur Neuropsychopharmacol 2008; 18: 787-793
    CrossrefPubMedGoogle Scholar
  • 2 Association AP. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159: 1-50
    CrossrefPubMedGoogle Scholar
  • 3 Berk M, Berk L, Castle D. A collaborative approach to the treatment alliance in bipolar disorder. Bipolar Disord 2004; 6: 504-518
    CrossrefPubMedGoogle Scholar
  • 4 Yatham LN, Kennedy SH, O'Donovan C et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006; 8: 721-739
    CrossrefPubMedGoogle Scholar
  • 5 National Collaborating Centre for Mental Health (UK). Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. NICE clinical guideline 38. Leicester (UK): British Psychological Society; 2006
    PubMedGoogle Scholar
  • 6 DGBS e. V. und DGPPN e. V.: S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen. Langversion 1.8. Mai 2012, letzte Anpassung Januar 2014
    PubMedGoogle Scholar
  • 7 Saß H, Wittchen HU, Zaudig M. Diagnostisches und statistisches Manual psychischer Störungen DSM-IV. Göttingen: Hogrefe; 1996
    Google Scholar
  • 8 Association AP. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington DC: American Psychiatric Association; 1994
    Google Scholar
  • 9 WHO. Internationale Klassifikation psychischer Störungen: ICD-10 Kapitel V, Klinisch-diagnostische Leitlinien. 4. Aufl. Bern: Hans Huber; 2000
    Google Scholar
  • 10 Tohen M, Frank E, Bowden CL et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009; 11: 453-473
    CrossrefPubMedGoogle Scholar
  • 11 Bauer MS, Mitchner L. What is a "mood stabilizer"? An evidence-based response. Am J Psychiatry 2004; 161: 3-18
    CrossrefPubMedGoogle Scholar
  • 12 Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry 2002; 63: 146-151
    CrossrefPubMedGoogle Scholar
  • 13 Keck PE, Calabrese JR, McQuade RD et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. Journal Clin Psychiatry 2006; 67: 626-637
    PubMedGoogle Scholar
  • 14 Keck PE, Calabrese JR, McIntyre RS et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68: 1480-1491
    CrossrefPubMedGoogle Scholar
  • 15 Krüger S. Olanzapin in der Behandlung bipolarer affektiver Erkrankungen. Psychiatr Prax 2006; 33 (Suppl. 01) S18-S26
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Geddes JR, Burgess S, Hawton K et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161: 217-222
    CrossrefPubMedGoogle Scholar
  • 17 Smith LA, Cornelius V, Warnock A et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007; 9: 394-412
    CrossrefPubMedGoogle Scholar
  • 18 Severus WE, Kleindienst N, Seemuller F et al. What is the optimal serum lithium level in the long-term treatment of bipolar disorder--a review?. Bipolar Disord 2008; 10: 231-237
    CrossrefPubMedGoogle Scholar
  • 19 Tohen M, Calabrese JR, Sachs GS et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163: 247-256
    CrossrefPubMedGoogle Scholar
  • 20 Tohen M, Greil W, Calabrese JR et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162: 1281-1290
    Google Scholar
  • 21 Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-1024
    CrossrefPubMedGoogle Scholar
  • 22 Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400
    CrossrefPubMedGoogle Scholar
  • 23 Vieta E, Suppes T, Eggens I et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008; 109: 251-263
    CrossrefPubMedGoogle Scholar
  • 24 Vieta E, Berk M, Wang W et al. Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. J Affect Disord 2009; 119: 22-27
    CrossrefPubMedGoogle Scholar
  • 25 Colom F, Vieta E, Daban C et al. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J Affect Disord 2006; 93: 13-17
    CrossrefPubMedGoogle Scholar
  • 26 Baldessarini RJ, Tondo L, Davis P et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006; 8: 625-639
    Google Scholar
  • 27 Cipriani A, Pretty H, Hawton K et al. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-1819
    CrossrefPubMedGoogle Scholar
  • 28 Maj M, Pirozzi R, Starace F. Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients. J Affect Disord 1989; 17: 237-241
    CrossrefPubMedGoogle Scholar
  • 29 Faedda GL, Baldessarini RJ, Tohen M et al. Episode sequence in bipolar disorder and response to lithium treatment. Am J Psychiatry 1991; 148: 1237-1239
    CrossrefPubMedGoogle Scholar
  • 30 Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. Jama 1994; 271: 918-924
    CrossrefPubMedGoogle Scholar
  • 31 Abou-Saleh MT, Coppen A. Who responds to prophylactic lithium?. J Affect Disord 1986; 10: 115-125
    CrossrefPubMedGoogle Scholar
  • 32 Maj M. Effectiveness of lithium prophylaxis in schizoaffective psychoses: application of a polydiagnostic approach. Acta Psychiatr Scand 1984; 70: 228-234
    CrossrefPubMedGoogle Scholar
  • 33 Sarantidis D, Waters B. Predictors of lithium prophylaxis effectiveness. Prog Neuropsychopharmacol 1981; 5: 507-510
    CrossrefPubMedGoogle Scholar
  • 34 Abou-Saleh MT. Platelet MAO, personality and response to lithium prophylaxis. J Affect Disord 1983; 5: 55-65
    CrossrefPubMedGoogle Scholar
  • 35 Gaviria M, Flaherty J, Val E. A comparison of bipolar patients with and without a borderline personality disorder. Psychiatr J Univ Ott 1982; 7: 190-195
    PubMedGoogle Scholar
  • 36 Kutcher SP, Marton P, Korenblum M. Adolescent bipolar illness and personality disorder. J Am Acad Child Adolesc Psychiatry 1990; 29: 355-358
    CrossrefPubMedGoogle Scholar
  • 37 Post RM, Leverich GS, Kupka RW et al. Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry 2010; 71: 864-872
    CrossrefPubMedGoogle Scholar
  • 38 Franchini L, Zanardi R, Smeraldi E et al. Early onset of lithium prophylaxis as a predictor of good long-term outcome. Eur Arch Psychiatry Clin Neurosci 1999; 249: 227-230
    CrossrefPubMedGoogle Scholar
  • 39 Garcia-Lopez A, Ezquiaga E, Nieves P et al. Clinical predictors of long-term outcome of lithium prophylaxis in bipolar disorder. Actas Esp Psiquiatr 2001; 29: 327-332
    PubMedGoogle Scholar
  • 40 Yatham LN, Kennedy SH, Schaffer A et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11: 225-255
    CrossrefPubMedGoogle Scholar
  • 41 Goodwin GM. Consensus Group of the British Association for P. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23: 346-388
    CrossrefPubMedGoogle Scholar
  • 42 Licht RW, Vestergaard P, Kessing LV et al. Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Acta Psychiatr Scand Suppl 2003; 419: 1-22
    PubMedGoogle Scholar
  • 43 Sachs GS, Printz DJ, Kahn DA et al. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med 2000; Spec No: 1-104
    PubMedGoogle Scholar
  • 44 Nolen WA, Kupka RW, Schulte PFJ et al. Richtlijn bipolaire stoornissen. Utrecht 2008
    PubMedGoogle Scholar
  • 45 Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64: 543-552
    Google Scholar
  • 46 Rihmer Z, Pestality P. Bipolar II disorder and suicidal behavior. Psychiatr Clin North Am 1999; 22: 667-673
    CrossrefPubMedGoogle Scholar
  • 47 Baastrup PC. The Use of Lithium in Manic-Depressive Psychosis. Compr Psychiatry 1964; 10: 396-408
    PubMedGoogle Scholar
  • 48 Hartigan GP. The Use of Lithium Salts in Affective Disorders. Br J Psychiatry 1963; 109: 810-814
    CrossrefPubMedGoogle Scholar
  • 49 Baastrup PC, Poulsen JC, Schou M et al. Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet 1970; 2: 326-330
    PubMedGoogle Scholar
  • 50 Coppen A, Noguera R, Bailey J et al. Prophylactic lithium in affective disorders. Controlled trial. Lancet 1971; 2: 275-279
    PubMedGoogle Scholar
  • 51 Cundall RL, Brooks PW, Murray LG. A controlled evaluation of lithium prophylaxis in affective disorders. Psychol Med 1972; 2: 308-311
    CrossrefPubMedGoogle Scholar
  • 52 Dunner DL, Stallone F, Fieve RR. Lithium carbonate and affective disorders. V: A double-blind study of prophylaxis of depression in bipolar illness. Arch Gen Psychiatry 1976; 33: 117-120
    CrossrefPubMedGoogle Scholar
  • 53 Fieve RR, Dunner DL, Kumbaraci T et al. Lithium carbonate prophylaxis of depression in three subtypes in primary affective disorder. Pharmakopsychiatr Neuropsychopharmakol 1976; 9: 100-107
    Article in Thieme ConnectPubMedGoogle Scholar
  • 54 Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Pres; 2007
    Google Scholar
  • 55 Maj M. The impact of lithium prophylaxis on the course of bipolar disorder: a review of the research evidence. Bipolar Disord 2000; 2: 93-101
    CrossrefPubMedGoogle Scholar
  • 56 Licht RW. Lithium: still a major option in the management of bipolar disorder. CNS Neurosci Ther 2012; 18: 219-226
    CrossrefPubMedGoogle Scholar
  • 57 Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57: 481-489
    CrossrefPubMedGoogle Scholar
  • 58 Bowden CL, Lecrubier Y, Bauer M et al. Maintenance therapies for classic and other forms of bipolar disorder. J Affect Disord 2000; 59 (Suppl. 01) S57-S67
    CrossrefPubMedGoogle Scholar
  • 59 Goodwin GM, Geddes JR. Latest maintenance data on lithium in bipolar disorder. Eur Neuropsychopharmacol 2003; 13 (Suppl. 02) S51-S55
    CrossrefPubMedGoogle Scholar
  • 60 Kane JM, Quitkin FM, Rifkin A et al. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982; 39: 1065-1069
    CrossrefPubMedGoogle Scholar
  • 61 Geddes JR. BALANCE investigators and collaborators et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375: 385-395
    CrossrefPubMedGoogle Scholar
  • 62 Mander AJ, Loudon JB. Rapid recurrence of mania following abrupt discontinuation of lithium. Lancet 1988; 2: 15-17
    PubMedGoogle Scholar
  • 63 Burrow GN, Burke WR, Himmelhoch JM et al. Effect of lithium on thyroid function. J Clin Endocrinol Metab 1971; 32: 647-652
    CrossrefPubMedGoogle Scholar
  • 64 Schiemann U, Hengst K. Thyroid echogenicity in manic-depressive patients receiving lithium therapy. J Affect Disord 2002; 70: 85-90
    CrossrefPubMedGoogle Scholar
  • 65 Mak TW, Shek CC, Chow CC et al. Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitudinal study. J Clin Endocrinol Metab 1998; 83: 3857-3859
    PubMedGoogle Scholar
  • 66 Berger M, Riedel M, Tomova N et al. Do current screening recommendations allow for early detection of lithium-induced hyperparathyroidism in patients with bipolar disorder?. Int J Bipolar Disord 2013; 1: 7
    CrossrefPubMedGoogle Scholar
  • 67 Yamaki M, Kusano E, Tetsuka T et al. Cellular mechanism of lithium-induced nephrogenic diabetes insipidus in rats. Am J Physiol 1991; 261: F505-F511
    PubMedGoogle Scholar
  • 68 Tredget J, Kirov A, Kirov G. Effects of chronic lithium treatment on renal function. J Affect Disord 2010; 126: 436-440
    CrossrefPubMedGoogle Scholar
  • 69 Bendz H, Schon S, Attman PO et al. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int 2010; 77: 219-224
    CrossrefPubMedGoogle Scholar
  • 70 McKnight RF, Adida M, Budge K et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379: 721-728
    CrossrefPubMedGoogle Scholar
  • 71 Bowden CL, Singh V. Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr Scand Suppl 2005; 13-20
    PubMedGoogle Scholar
  • 72 Gyulai L, Bowden CL, McElroy SL et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003; 28: 1374-1382
    CrossrefPubMedGoogle Scholar
  • 73 Tohen M, Ketter TA, Zarate CA et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003; 160: 1263-1271
    PubMedGoogle Scholar
  • 74 Rasgon NL, Altshuler LL, Fairbanks L et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005; 7: 246-259
    CrossrefPubMedGoogle Scholar
  • 75 European Medicines Agency. Questions and answers on the review of medicines containing valproate for use in bipolar disorder. EM Agency; 2010
    PubMedGoogle Scholar
  • 76 Greil W, Ludwig-Mayerhofer W, Erazo N et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders--a randomised study. J Affect Disord 1997; 43: 151-161
    CrossrefPubMedGoogle Scholar
  • 77 Hartong EG, Moleman P, Hoogduin CA et al. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003; 64: 144-151
    CrossrefPubMedGoogle Scholar
  • 78 Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000; 42 (Suppl. 01) S2-S10
    CrossrefPubMedGoogle Scholar
  • 79 Greil W, Kleindienst N. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol 1999; 14: 283-285
    CrossrefPubMedGoogle Scholar
  • 80 Greil W, Kleindienst N. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol 1999; 14: 277-281
    CrossrefPubMedGoogle Scholar
  • 81 Licht RW, Nielsen JN, Gram LF et al. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord 2010; 12: 483-493
    CrossrefPubMedGoogle Scholar
  • 82 Fountoulakis KN, Vieta E. Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Ann Gen Psychiatry 2009; 8: 16
    CrossrefPubMedGoogle Scholar
  • 83 Marcus R, Khan A, Rollin L et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011; 13: 133-144
    CrossrefPubMedGoogle Scholar
  • 84 Weisler RH, Nolen WA, Neijber A et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 2011; 72: 1452-1464
    CrossrefPubMedGoogle Scholar
  • 85 Young AH, McElroy SL, Olausson B et al. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J Biol Psychiatry 2014; 15: 96-112
    CrossrefPubMedGoogle Scholar
  • 86 Suppes T, Vieta E, Liu S et al. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009; 166: 476-488
    CrossrefPubMedGoogle Scholar
  • 87 Quiroz JA, Yatham LN, Palumbo JM et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010; 68: 156-162
    CrossrefPubMedGoogle Scholar
  • 88 Bowden CL, Vieta E, Ice KS et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010; 71: 130-137
    CrossrefPubMedGoogle Scholar
  • 89 Keck PE, Versiani M, Potkin S et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160: 741-748
    CrossrefPubMedGoogle Scholar
  • 90 Seemuller F, Forsthoff A, Dittmann S et al. The safety and tolerability of atypical antipsychotics in bipolar disorder. Expert opinion on drug safety 2005; 4: 849-868
    CrossrefPubMedGoogle Scholar
  • 91 Vieta E, Grunze H. Bipolar disorder – a focus on depression. N Engl J Med 2011; 364: 1581 Author Reply 1582
    PubMedGoogle Scholar
  • 92 Frye MA. Clinical practice. Bipolar disorder--a focus on depression. N Engl J Med 2011; 364: 51-59
    CrossrefPubMedGoogle Scholar
  • 93 Frye MA, Helleman G, McElroy SL et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry 2009; 166: 164-172
    CrossrefPubMedGoogle Scholar
  • 94 Leverich GS, Altshuler LL, Frye MA et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006; 163: 232-239
    CrossrefPubMedGoogle Scholar
  • 95 Nolen WA, Kupka RW, Hellemann G et al. Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand 2007; 115: 360-365
    CrossrefPubMedGoogle Scholar
  • 96 Altshuler L, Kiriakos L, Calcagno J et al. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. J Clin Psychiatry 2001; 62: 612-616
    CrossrefPubMedGoogle Scholar
  • 97 Amsterdam JD, Luo L, Shults J. Efficacy and mood conversion rate during long-term fluoxetine v. lithium monotherapy in rapid- and non-rapid-cycling bipolar II disorder. Br J Psychiatry 2013; 202: 301-306
    CrossrefPubMedGoogle Scholar
  • 98 Grande I, de Arce R, Jimenez-Arriero MA et al. Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES). Int J Neuropsychopharmacol 2013; 16: 513-523
    CrossrefPubMedGoogle Scholar
  • 99 Scott J, Colom F, Vieta E. A meta-analysis of relapse rates with adjunctive psychological therapies compared to usual psychiatric treatment for bipolar disorders. Int J Neuropsychopharmacol 2007; 10: 123-129
    CrossrefPubMedGoogle Scholar
  • 100 Colom F, Vieta E, Martinez-Aran A et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003; 60: 402-407
    CrossrefPubMedGoogle Scholar
  • 101 Seemuller F, Berger M, Musil R et al. The challenge of treating bipolar outpatients. Fortschritte der Neurologie-Psychiatrie 2013; 81 (Suppl. 01) S35-S39
    PubMedGoogle Scholar
  • 102 Quill TE, Brody H. Physician recommendations and patient autonomy: finding a balance between physician power and patient choice. Ann Intern Med 1996; 125: 763-769
    CrossrefPubMedGoogle Scholar
  • 103 Zeber JE, Copeland LA, Good CB et al. Therapeutic alliance perceptions and medication adherence in patients with bipolar disorder. J Affect Disord 2008; 107: 53-62
    CrossrefPubMedGoogle Scholar
  • 104 Malhi GS, Ivanovski B, Hadzi-Pavlovic D et al. Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord 2007; 9: 114-125
    CrossrefPubMedGoogle Scholar
  • 105 Ayuso-Mateos JL. Global Burden of Bipolar Disorder in the Year 2000. Geneva: World Health Organization; Stand: 21.6.2006
    PubMedGoogle Scholar
  • 106 Murray CL, Lopez AD. The Global Burden of Disease. Cambridge: Harvard University Press; 1996
    Google Scholar